Cargando…
Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine
Treatment resistant depression (TRD) is a global health concern affecting a large proportion of depressed patients who then require novel therapeutic options. One such treatment option that has received some attention in the past several years is vagal nerve stimulation (VNS). The present review bri...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Neuropsychopharmacology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153868/ https://www.ncbi.nlm.nih.gov/pubmed/25191499 http://dx.doi.org/10.9758/cpn.2014.12.2.83 |
_version_ | 1782333341122428928 |
---|---|
author | Shah, Aparna Carreno, Flavia Regina Frazer, Alan |
author_facet | Shah, Aparna Carreno, Flavia Regina Frazer, Alan |
author_sort | Shah, Aparna |
collection | PubMed |
description | Treatment resistant depression (TRD) is a global health concern affecting a large proportion of depressed patients who then require novel therapeutic options. One such treatment option that has received some attention in the past several years is vagal nerve stimulation (VNS). The present review briefly describes the relevance of this treatment in the light of other existing pharmacological and non-pharmacological options. It then summarizes clinical findings with respect to the efficacy of VNS. The anatomical rationale for its efficacy and other potential mechanisms of its antidepressant effects as compared to those employed by classical antidepressant drugs are discussed. VNS has been approved in some countries and has been used for patients with TRD for quite some time. A newer, fast-acting, non-invasive pharmacological option called ketamine is currently in the limelight with reference to TRD. This drug is currently in the investigational phase but shows promise. The clinical and preclinical findings related to ketamine have also been summarized and compared with those for VNS. The role of neurotrophin factors, specifically brain derived neurotrophic factor and its receptor, in the beneficial effects of both VNS and ketamine have been highlighted. It can be concluded that both these therapeutic modalities, while effective, need further research that can reveal specific targets for intervention by novel drugs and address concerns related to side-effects, especially those seen with ketamine. |
format | Online Article Text |
id | pubmed-4153868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Korean College of Neuropsychopharmacology |
record_format | MEDLINE/PubMed |
spelling | pubmed-41538682014-09-04 Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine Shah, Aparna Carreno, Flavia Regina Frazer, Alan Clin Psychopharmacol Neurosci Review Treatment resistant depression (TRD) is a global health concern affecting a large proportion of depressed patients who then require novel therapeutic options. One such treatment option that has received some attention in the past several years is vagal nerve stimulation (VNS). The present review briefly describes the relevance of this treatment in the light of other existing pharmacological and non-pharmacological options. It then summarizes clinical findings with respect to the efficacy of VNS. The anatomical rationale for its efficacy and other potential mechanisms of its antidepressant effects as compared to those employed by classical antidepressant drugs are discussed. VNS has been approved in some countries and has been used for patients with TRD for quite some time. A newer, fast-acting, non-invasive pharmacological option called ketamine is currently in the limelight with reference to TRD. This drug is currently in the investigational phase but shows promise. The clinical and preclinical findings related to ketamine have also been summarized and compared with those for VNS. The role of neurotrophin factors, specifically brain derived neurotrophic factor and its receptor, in the beneficial effects of both VNS and ketamine have been highlighted. It can be concluded that both these therapeutic modalities, while effective, need further research that can reveal specific targets for intervention by novel drugs and address concerns related to side-effects, especially those seen with ketamine. Korean College of Neuropsychopharmacology 2014-08 2014-08-12 /pmc/articles/PMC4153868/ /pubmed/25191499 http://dx.doi.org/10.9758/cpn.2014.12.2.83 Text en Copyright© 2014, Korean College of Neuropsychopharmacology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Shah, Aparna Carreno, Flavia Regina Frazer, Alan Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine |
title | Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine |
title_full | Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine |
title_fullStr | Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine |
title_full_unstemmed | Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine |
title_short | Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine |
title_sort | therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153868/ https://www.ncbi.nlm.nih.gov/pubmed/25191499 http://dx.doi.org/10.9758/cpn.2014.12.2.83 |
work_keys_str_mv | AT shahaparna therapeuticmodalitiesfortreatmentresistantdepressionfocusonvagalnervestimulationandketamine AT carrenoflaviaregina therapeuticmodalitiesfortreatmentresistantdepressionfocusonvagalnervestimulationandketamine AT frazeralan therapeuticmodalitiesfortreatmentresistantdepressionfocusonvagalnervestimulationandketamine |